PLGA-Rhodamine used in development of micropatches for immunotherapy of cancer.

 

B-Cells are macrophages which play a key role in the immune response. These cells can be leveraged to modify the adaptive immune response. Researchers at Harvard University, used PLGA-Rhodamine (Cat# AV011) from PolySciTech Division of Akina, Inc. (www.polyscitech.com) as part of developing patches to target B-cells and induce them to raise an immune response against cancer. This research holds promise to provide for therapy against cancer. Read more: Prakash, Supriya, Ninad Kumbhojkar, Alexander P. Gottlieb, Kyung-Soo Park, Neha Kapate, and Samir Mitragotri. "Polymer Micropatches as B-Cell Engagers." ACS Applied Materials & Interfaces (2024). https://pubs.acs.org/doi/abs/10.1021/acsami.4c04385

“ABSTRACT: B cells, despite their several unique functionalities, remain largely untapped for use as an adoptive cell therapy and are limited to in vitro use for antibody production. B cells can be easily sourced, they possess excellent lymphoid-homing capabilities, and they can act as antigen-presenting cells (APCs), offering an alternative to dendritic cells (DCs), which have shown limited efficacy in the clinical setting. Soluble factors such as IL-4 and anti-CD40 antibody can enhance the activation, survival, and antigen-presenting capabilities of B cells; however, it is difficult to attain sufficiently high concentrations of these biologics to stimulate B cells in vivo. Micropatches as Cell Engagers (MACE) are polymeric microparticles, surface functionalized with anti-CD40 and anti-IgM, which can attach to B cells and simultaneously engage multiple B-cell receptors (BCR) and CD40 receptors. Stimulation of these receptors through MACE, unlike free antibodies, enhanced the display of costimulatory molecules on the B-cell surface, increased B-cell viability, and improved antigen presentation by B cells to T cells in vitro. B-cell activation by MACE further synergized with soluble IL-4 and anti-CD40. MACE also elicited T-cell chemokine secretion by B cells. Upon intravenous adoptive transfer, MACE-bound B cells homed to the spleen and lymph nodes, key sites for antigen presentation to T cells. Adoptive transfer of MACE-B cells pulsed with the CD4+ and CD8+ epitopes of ovalbumin significantly delayed tumor progression in a murine subcutaneous EG7-OVA tumor model, demonstrating the functional benefit conferred to B cells by MACE. KEYWORDS: B cells, B-cell activation, MACE, APC, cellular vaccine, cancer vaccine”

AV011: https://akinainc.com/polyscitech/products/polyvivo/index.php?highlight=AV011#h

Video: https://youtu.be/XMJp_8qGyZs

NEW: Corbion Purasorb® Polymers: https://akinainc.com/polyscitech/products/purasorb/

NEW: Ashland-TM products: https://akinainc.com/polyscitech/products/ashland/